Filters: author is Ploeger [Clear All Filters]
- 2009
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography,
Epilepsia, vol. 50, no. 1, pp. 88-98.
Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex,
Anesthesiology, vol. 110, no. 1, pp. 95-105.
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients,
Ther Drug Monit, vol. 31, no. 2, pp. 187-97.
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling,
Drug Metab Pharmacokinet, vol. 24, no. 1, pp. 3-15.
- 2008
Extensions to the visual predictive check to facilitate model performance evaluation,
J Pharmacokinet Pharmacodyn, vol. 35, no. 2, pp. 185-202.
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research,
Trends Pharmacol Sci, vol. 29, no. 4, pp. 186-91.
- 2007
Application of the convection-dispersion equation to modelling oral drug absorption,
Bull Math Biol, vol. 69, no. 1, pp. 181-95.
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis,
Annu Rev Pharmacol Toxicol, vol. 47, pp. 357-400.
- 2006
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus,
J Pharmacokinet Pharmacodyn, vol. 33, no. 3, pp. 313-43.
- 2005
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography,
Mol Imaging Biol, vol. 7, no. 6, pp. 411-21.



